Editing Digoxin (section)

== Further reading ==
{{refbegin}}
* {{cite book | vauthors = Rang HP, Dale MM, Ritter JM, Moore PK | title = Pharmacology | publisher = Churchill Livingstone | location = Edinburgh | year = 2003 | isbn = 0-443-07145-4 | edition = 5th }}
* [[Summary of Product Characteristics]], Digoxin 0.125&nbsp;mg, Zentiva.
* {{cite book | vauthors = Lüllmann H, Kuschinsky G, Mohr K, Wehling M | title = Pharmakologie und Toxikologie | publisher = Georg Thieme Verlag | year = 2003 | isbn = 3-13-368515-5 | edition = 15th }}
* [[Lanatoside C]] (isolanid, Cedilanid – four glycoside analog), [[Digoxigenin]] (aglycone analog)
* {{cite journal | vauthors = Goldberger ZD, Alexander GC | title = Digitalis use in contemporary clinical practice: refitting the foxglove | journal = JAMA Internal Medicine | volume = 174 | issue = 1 | pages = 151–154 | date = January 2014 | pmid = 24217624 | doi = 10.1001/jamainternmed.2013.10432 }}
{{refend}}

{{Cardiac glycosides}}
{{Antiarrhythmic agents}}
{{GlaxoSmithKline}}
{{Portal bar|Medicine}}

[[Category:Cardenolides]]
[[Category:IARC Group 2B carcinogens]]
[[Category:Inotropic agents]]
[[Category:Peripherally selective drugs]]
[[Category:World Health Organization essential medicines]]
[[Category:Wikipedia medicine articles ready to translate]]